John Curtin, Keith Eldridge, Mary-Elodine D'silva, Paul Howard
{"title":"姑息医学中的皮下抗生素:回顾性图表回顾。","authors":"John Curtin, Keith Eldridge, Mary-Elodine D'silva, Paul Howard","doi":"10.1136/spcare-2025-005676","DOIUrl":null,"url":null,"abstract":"<p><strong>Objectives: </strong>To investigate the use and safety of subcutaneous (SC) antibiotics for infection and symptom control in the palliative setting.</p><p><strong>Methods: </strong>We conducted a retrospective chart review of the use of SC antibiotics since it was introduced to our palliative care service 7 years ago. All records were examined to ascertain therapeutic aim and tolerability.</p><p><strong>Results: </strong>SC antibiotics were administered to 87 patients (79% had cancer) on 112 occasions (for infection, 105/112, or symptom control, 7/112) in the inpatient hospice or home. 85% wanted to avoid hospitalisation and requested active treatment in situ. Reasons for SC rather than intravenous administration included venous fragility and lack of an available cannulator. Piperacillin/tazobactam was the most common antibiotic given. Of the occasions when treating for infection, the respiratory tract was the most common site; half survived beyond 21 days. Of those used for symptoms, antibiotics appeared helpful in 3/7. Adverse events led to discontinuation in 7/112 (<i>Clostridium difficile</i>, generalised rash or SC site problems in 1, 1 and 5/112, respectively).</p><p><strong>Conclusions: </strong>SC antibiotics appear well tolerated in the palliative setting and could be a useful option in selected patients who want to avoid hospitalisation but receive active treatment in situ. Thus, we believe that further research is warranted.</p>","PeriodicalId":9136,"journal":{"name":"BMJ Supportive & Palliative Care","volume":" ","pages":""},"PeriodicalIF":1.8000,"publicationDate":"2025-06-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Subcutaneous antibiotics in palliative medicine: Retrospective chart review.\",\"authors\":\"John Curtin, Keith Eldridge, Mary-Elodine D'silva, Paul Howard\",\"doi\":\"10.1136/spcare-2025-005676\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Objectives: </strong>To investigate the use and safety of subcutaneous (SC) antibiotics for infection and symptom control in the palliative setting.</p><p><strong>Methods: </strong>We conducted a retrospective chart review of the use of SC antibiotics since it was introduced to our palliative care service 7 years ago. All records were examined to ascertain therapeutic aim and tolerability.</p><p><strong>Results: </strong>SC antibiotics were administered to 87 patients (79% had cancer) on 112 occasions (for infection, 105/112, or symptom control, 7/112) in the inpatient hospice or home. 85% wanted to avoid hospitalisation and requested active treatment in situ. Reasons for SC rather than intravenous administration included venous fragility and lack of an available cannulator. Piperacillin/tazobactam was the most common antibiotic given. Of the occasions when treating for infection, the respiratory tract was the most common site; half survived beyond 21 days. Of those used for symptoms, antibiotics appeared helpful in 3/7. Adverse events led to discontinuation in 7/112 (<i>Clostridium difficile</i>, generalised rash or SC site problems in 1, 1 and 5/112, respectively).</p><p><strong>Conclusions: </strong>SC antibiotics appear well tolerated in the palliative setting and could be a useful option in selected patients who want to avoid hospitalisation but receive active treatment in situ. Thus, we believe that further research is warranted.</p>\",\"PeriodicalId\":9136,\"journal\":{\"name\":\"BMJ Supportive & Palliative Care\",\"volume\":\" \",\"pages\":\"\"},\"PeriodicalIF\":1.8000,\"publicationDate\":\"2025-06-27\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"BMJ Supportive & Palliative Care\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1136/spcare-2025-005676\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q3\",\"JCRName\":\"HEALTH CARE SCIENCES & SERVICES\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"BMJ Supportive & Palliative Care","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1136/spcare-2025-005676","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"HEALTH CARE SCIENCES & SERVICES","Score":null,"Total":0}
Subcutaneous antibiotics in palliative medicine: Retrospective chart review.
Objectives: To investigate the use and safety of subcutaneous (SC) antibiotics for infection and symptom control in the palliative setting.
Methods: We conducted a retrospective chart review of the use of SC antibiotics since it was introduced to our palliative care service 7 years ago. All records were examined to ascertain therapeutic aim and tolerability.
Results: SC antibiotics were administered to 87 patients (79% had cancer) on 112 occasions (for infection, 105/112, or symptom control, 7/112) in the inpatient hospice or home. 85% wanted to avoid hospitalisation and requested active treatment in situ. Reasons for SC rather than intravenous administration included venous fragility and lack of an available cannulator. Piperacillin/tazobactam was the most common antibiotic given. Of the occasions when treating for infection, the respiratory tract was the most common site; half survived beyond 21 days. Of those used for symptoms, antibiotics appeared helpful in 3/7. Adverse events led to discontinuation in 7/112 (Clostridium difficile, generalised rash or SC site problems in 1, 1 and 5/112, respectively).
Conclusions: SC antibiotics appear well tolerated in the palliative setting and could be a useful option in selected patients who want to avoid hospitalisation but receive active treatment in situ. Thus, we believe that further research is warranted.
期刊介绍:
Published quarterly in print and continuously online, BMJ Supportive & Palliative Care aims to connect many disciplines and specialties throughout the world by providing high quality, clinically relevant research, reviews, comment, information and news of international importance.
We hold an inclusive view of supportive and palliative care research and we are able to call on expertise to critique the whole range of methodologies within the subject, including those working in transitional research, clinical trials, epidemiology, behavioural sciences, ethics and health service research. Articles with relevance to clinical practice and clinical service development will be considered for publication.
In an international context, many different categories of clinician and healthcare workers do clinical work associated with palliative medicine, specialist or generalist palliative care, supportive care, psychosocial-oncology and end of life care. We wish to engage many specialties, not only those traditionally associated with supportive and palliative care. We hope to extend the readership to doctors, nurses, other healthcare workers and researchers in medical and surgical specialties, including but not limited to cardiology, gastroenterology, geriatrics, neurology, oncology, paediatrics, primary care, psychiatry, psychology, renal medicine, respiratory medicine.